1. Introduction {#s0005}
===============

1.1. Introduction to micro-emulsion {#s0010}
-----------------------------------

The concept of micro-emulsion was first introduced in 1940 by Hoar and Schulman ([@b0070]). Micro-emulsion is a clear, stable, isotropic mixture of oil, water and surfactant frequently used in combination with a co-surfactant. Micro-emulsion based drug delivery consists of delivering a drug dissolved in a mixture of one or more excipients which may be a mono, di and tri-glycerides, lipophilic and hydrophilic surfactants and a co-surfactant ([@b0055]). When the drug is delivered through lipid formulation, it remains in the dissolved state throughout its transit. The absorption of drug presented in solubilized form within a colloidal dispersion is enhanced since the drug dissolution step is partially divided.

In the year 2000, Pouton classified lipid based formulations into three categories based on their composition and properties as in [Table 1](#t0005){ref-type="table"}.

Micro-emulsions are isotropic mixtures of oil, surfactant, co-surfactant (solubilizer) and drug falling under class III B in [Table 1](#t0005){ref-type="table"}. The basic principle of this system is to form o/w type of micro-emulsion under gentle agitation following dilution by aqueous phase. This micro-emulsion keeps the drug in a solubilized form and small sized formed droplets provide large interfacial area for drug absorption. Apart from solubilization, the presence of lipid in a formulation further helps to improve bioavailability by enhancing the permeability of the drug ([@b0110]) [Table 2](#t0010){ref-type="table"}.

Micro-emulsion is prepared when entropy changes that fevers dispersion is greater than the free energy required to increase the surface area between the oil and aqueous phase of the dispersion. The change in free energy (ΔG) associated with the process of emulsification, ignoring the free energy of mixing, can be expressed by ([@b0080])$$\Delta\mathbf{G} = \sum\mathbf{N}_{\mathbf{i}}4\mathbf{\pi}\mathbf{r}_{\mathbf{i}}2\mathbf{\sigma}$$where ***N~i~*** = the number of droplets of radius ***r~i~***~,~ ***σ*** = the interfacial energy.

Micro-emulsification will occur only when the interfacial energy is low. However, emulsions are not thermodynamically stable as the oil phase and the aqueous phase will tend to separate with time to reduce the interfacial area and also free energy of the system. Therefore, the presence of surfactants will help to reduce interfacial tensions by forming a barrier around the oil droplets and hence the free energy of the systems. On the other hand, related emulsification with the formation of liquid crystalline phase. Liquid crystalline phase is the phase between liquid and crystal phases. A liquid crystal has both the properties of a crystal as well as a liquid. When additional energy is exerted onto the liquid crystalline phase, it will turn into liquid phase. For micro-emulsifying systems, when the oil phase is introduced into the aqueous phase with gentle agitation, the aqueous phase will penetrate through the interface into the oil phase until the interface of the two phases is disrupted. Consequently, oil droplets are formed resulting in emulsification. Thus, the ease of emulsification is governed by the ease of water penetration into the various liquid crystals or gel phases formed on the surface of droplets. The liquid crystal formation surrounding the oil droplets will increase the stability of the emulsion. Nevertheless, the relationship between liquid crystal formation and emulsion formation could be more complicated as it appeared to be. Various factors can affect the process of emulsification, such as the nature of oil/surfactant pair, the surfactant concentration used as well as the temperature. Moreover, the presence of drug compound will alter the emulsion characteristics, probably by interacting with the liquid crystalline phase ([@b0070]) [Table 3](#t0015){ref-type="table"}.

1.2. Introduction to emulgel {#s0015}
----------------------------

When both emulsion and gel are used in a combined form the dosage form prepared is named as Emulgel ([@b0085]). As the name suggests it is the combination of emulsion and gel ([@b0005]). Therefore, it has been recently used as vehicle to deliver various drugs to the skin for topical as well as systemic actions ([@b0010]). In fact, the presence of a gelling agent in water phase converts an ancient emulsion into emulgel ([@b0145]). The direct (oil-in-water) system is used to entrap lipophilic drugs, while hydrophilic drugs are encapsulated in the reverse (water-in-oil) system ([@b0065], [@b0150]). Emulsions have a certain degree of elegance and are easily washable whenever required ([@b0090]). They also have a high ability to penetrate the skin ([@b0085]). Topically used emulgels have several desirable properties like being thixotropic, greaseless, easily spreadable as well as removable, emollient, non-staining, water soluble, longer shelf-life, bio-friendly, transparent, pleasant appearance etc ([@b0050], [@b0115]).

1.3. Introduction to microemulgel {#s0020}
---------------------------------

When both micro-emulsion and gel are used in combination dosage forms the prepared formulations are called as microemulgel, having the advantages of both emulgel as well as micro-emulsion. Both hydrophilic and hydrophobic types of drugs are incorporated into dosage forms. They provide a large surface area for drug absorption and oil portion increases the bioavailability by improving permeability of drugs. Also the stability of micro-emulsion is increased when it is incorporated in gel. Over to micro-emulsions, microemulgels have a certain degree of elegance and easily washable whenever required.

1.4. Ideal characteristics of drug and excipients {#s0025}
-------------------------------------------------

There are some necessities of drug candidates and excipients used for topical or ophthalmic drug delivery system as listed in [Table 4](#t0020){ref-type="table"}.

Same way the excipients utilized should be IIG listed, GRAS listed or biologically safe, non-irritant, non-allergic, concentration under guideline, should have little or no deleterious effect on activity and stability of final product, compatible with API and other excipients etc.

2. Study protocol {#s0030}
=================

2.1. Aim {#s0035}
--------

Formulation, Development and Evaluation of Microemulgel.

2.2. Objective {#s0040}
--------------

•Prepared and optimized micro-emulsion from selected oil with emulsifier and co-emulsifier in which an API has the maximum solubility.•Optimized formula of microemulgel with different grades and different concentrations of the gelling agent by applying suitable statistical design.•To evaluate the combined effect of oil and API and compare it to API alone and available marketed preparation.

2.3. Rationale of study {#s0045}
-----------------------

•Microemulgel could bring about dual control release system i.e. gel and micro-emulsion with an increase in the pharmacological activity at the site of action and reduction in side effects with advantages of emulgel.•Oil probably is having more or less pharmacological property, surfactant and co-surfactant one from each category will be screened on the basis of solubility studies of API(s) in it, so the problem of solubility of API will be overcome.•Microemulgel formulation enhances the skin deposition of API, thereby presumably enhancing its therapeutic activity.

3. Methodology {#s0050}
==============

−Identification of API: As per pharmacopoeia procedure.−Scanning and Calibration curve of API in solvent and in Phosphate buffer at specific pH: As per pharmacopoeia procedure.−Identification of Excipients: As per pharmacopoeia procedure.−Short listing of oils that have no interference of absorbance of API (generally between 200 and 400 nm.)−Screening of oil among the shortlisted oils, emulsifier and co-emulsifier on the basis of solubility study.−Selection of emulsifier, co-emulsifier, its ratio and oil.−API-Excipients compatibility study.−Preparation of Pseudo ternary phase diagram.−Application of Mixture design.−Preparation of API loaded micro-emulsion.−Optimization of micro-emulsion: By design expert 9.0.3.1 software or Minitab 7.0.−Formulation and Development of API loaded microemulgel using suitable design of experiments.−**EVALUATION PARAMETERS**.

3.1. Preparation of micro-emulsion and microemulgel {#s0055}
---------------------------------------------------

•**Viscosity:** Brookfield Rotational viscometer will be used to measure viscosity ([@b0025]).•**pH:** pH will be measured by digital pH meter.•**Drug Content:** API based micro-emulsion will be subjected to extract API from micro-emulsion in appropriate solvent. Suitable dilution will be made with solvent and concentration will be measured by UV visible spectroscopic method at *λ~max~* nm by keeping solvent as reagent blank ([@b0140]).•**Centrifugation:** This parameter will be measured to evaluate physical stability. Micro-emulsion will be centrifuged at ambient temperature and 5000 RPM for 10 min to evaluate the system for creaming or phase separation. System will be observed visually for appearance ([@b0060]).•**Conductivity:** Electric conductivity of micro-emulsion will be measured at ambient temperature with digital conductometer.•**Dilution Test:** If continuous phase is added into micro-emulsion, it will not be separated into phases. 50--100 times continuous phase dilution of micro-emulsion will be carried out and visually checked for phase separation and clarity ([@b0075]).•**% Transmittance Measurement:** Micro-emulsion will be diluted to 50--100 times with continuous phase. The % transmittance of formulation was measured using UV Visible spectrophotometer at a specific wavelength using UV--Visible spectrophotometer against continuous phase as blank ([@b0095], [@b0135]).•**Zeta potential and Micelle Size analysis:** Micelle size, Size distribution and zeta potential of micro-emulsion will be determined using particle size analyzer ([@b0120]).•***In-vitro*-Release Study:** By Franz diffusion cell.

3.2. Evaluation of micro-emulsion and microemulgel {#s0060}
--------------------------------------------------

•**Physical Examinations:** Microemulgel was inspected for their color, homogeneity, consistency, texture, etc.•**pH:** pH of the 1% aqueous solution of the prepared microemulgels will be measured by digital pH meter.•**Spreadability Measurement:** To determine the spreadability of microemulgel, 0.5 gm of microemulgel will be placed within a circle of 1 cm diameter pre-marked on a glass plate, over which second plate will be placed. A weight of 5 gm will be allowed to rest on the upper glass plate for 5 min. The increase in diameter due to microemulgel, the spreading will be noted, which was cm/gm-sec ([@b0100]).•**Syneresis measurement test:** Upon standing sometimes gel system shrinks a bit and little liquid is pressed out. This phenomenon is known as Syneresis. In this test, microemulgel will be put in a cylindrical plastic tube with a perforated bottom which will be covered with filter paper (Whatman No. 41). These tubes will then placed in centrifuge tubes and centrifuged for 15 min. The cylindrical plastic tube and liquid which separated from microemulgel will be weighed. The percentage of Syneresis will be then calculated as ([@b0020]).$$\%\mspace{2mu}\text{of\ Syneresis} = \frac{\text{Weight\ of\ liquid\ separated\ from\ microemulgel}}{\text{Total\ Weight\ of\ microemulgel\ before\ centrifugation}} \times 100$$

•**Rheological study:** Mainly viscosity will be determined at 37 °C by means of Brookfield Viscometer.•**Drug content determination:** Drug content in microemulgel will be measured by dissolving 1gm of microemulgel in solvent by sonication. Absorbance will be measured after suitable dilution at *λ~max~* nm using UV spectrophotometer.•**Tube Test (Extrudability Test):** Force required to measure to extrude material from tube to evaluate microemulgel formulation for extrudability ([@b0130]).•***In-vitro*-Release Study:** By Franz diffusion cell at 37 °C.•**Drug release kinetics study:** Results of *in vitro* release profile obtained for all batches will be plotted in models of data treatment as•Zero -- order kinetic model -- % CPR Vs time.•First -- order kinetic model -- log cumulative percent drug remaining Vs time.•Higuchi's model -- cumulative percent drug released vs. square root of time.•Korsmeyer/Peppa's model -- log cumulative percent drug released Vs log time.•Hixson crowell model -- Cube root of % drug to be remaining Vs Time.•**Skin Irritation:** By Draize-patch test in Rabbit.•***In-vivo* study:** In animal study.−Optimization of Microemulgel.−**Microbial Assay of optimized microemulgel:** If an API has bacteriostatic or fungistatic activity then this test is required to be carried out. Ditch plate technique will be used for evaluation of bacteriostatic or fungistatic activity of an API ([@b0015]).$$\%\mspace{2mu}\text{inhibition} = \text{L}_{2}/\text{L}_{1} \times 100$$where L~1~ = Total length of the streaked culture, and L~2~ = length of inhibition

−**Accelerated Stability study of optimized microemulgel:** Sample of API loaded microemulgel will be sealed in ampoule and then placed in an accelerated stability chamber at 40 °C ± 5 °C temperature and 70% ± 5% RH. Duplicate sample will be withdrawn at 1, 2 and 3 months to evaluate their physicochemical parameters. The physical stability will be evaluated by visual inspection for physical changes such as phase separation and drug precipitation. Chemical stability will be expressed as the content of drug determined by UV visible spectroscopic method at *λ~max~* nm ([@b0045]).

4. Conclusion {#s0065}
=============

Mostly drugs are very much effective by oral and/or parenteral routes but have drawbacks of unwanted side effects, so the requirement of alternate routes of administration like topical, ophthalmic, vaginal etc. Mostly drugs are poorly water soluble, so have the problem of penetrating through the skin. Selection of oil, emulsifiers and co-emulsifiers for preparation are based on solubility of it in them, so the problem of solubility would be overcome. Oil portion has more or less pharmacological action and itself enhances penetration. Microemulgel enhances deposition of drug moieties at the site, so therapeutic activity is also increased. Stability is more as compared to micro-emulsion.

Peer review under responsibility of King Saud University.

###### 

Typical properties of Type I, II, IIIA, IIIB, and IV lipid formulations [@b0105].

  Sr. no.   Composition (%)                         Type I   Type II            Type IIIA            Type IIIB            Type IV
  --------- --------------------------------------- -------- ------------------ -------------------- -------------------- ---------
  1         Triglycerides or mixed glycerides       100      40--80             40--80               \<20                 --
  2         Surfactant                              --       20--60 (HLB\<12)   20--40 (HLB \> 11)   20--50 (HLB \> 11)   40--80
  3         Co-surfactant Hydrophilic co-solvents   --       --                 0--40                20--50               0--50
  4         Particle size of dispersion (nm)        Coarse   100--250           100--250             50--100              --

###### 

Advantages of micro-emulsion over emulsion ([@b0040].

  Sr. no.   Conventional (macro) emulsion                                                                               Micro-emulsion
  --------- ----------------------------------------------------------------------------------------------------------- ---------------------------------------------------------
  1         ![](fx1.gif)                                                                                                ![](fx2.gif)
  2         Two phase system renders it thermodynamically unstable                                                      One phase system renders it thermodynamically stable
  3         Poorer long term storage stability and often tend to coalesce, creaming/sedimentation or phase separation   Better long term storage stability
  4         Comparatively less bioavailability                                                                          Reduction in dose by the enhancement in bioavailability
  5         Comparatively less lipophilic transport                                                                     Enhanced lymphatic transport due to lipids [@b0035]
  6         High intra and inter subject variability                                                                    Reduced intra and inter subject variability [@b0030]
  7         Difficult manufacturing and scale up                                                                        Easy manufacture and scale up
  8         Thermodynamically unstable                                                                                  Excellent kinetic stability
  9         Cloudy white                                                                                                Clear
  10        Large input of energy for method of preparation                                                             No large input of energy for method of preparation
  11        Globule size more than 500 nm                                                                               Micelle size are 5--500 nm

###### 

Different types of dispersions.

  Appearance             Particle size range   Type
  ---------------------- --------------------- ----------------
  Transparent            10--140 nm            Micro-emulsion
  Translucent            140--200 nm           
  Turbid                 200 nm-few microns    Emulsion
  Presence of particle   Depended on API       Dispersion

###### 

Ideal properties of drug candidate [@b0125].

  Parameter                       Properties
  ------------------------------- -------------------------------------------
  Dose                            Should be low (less than 10 mg)
  Half-life                       10 hr or less
  Molecular weight                400 Dalton or less
  Partition coefficient           Log p (octanol--water) between −0.8 and 4
  Skin permeability coefficient   More than 0.5 × 10^−3^ cm/hr
  Skin reaction                   Non irritating and non-sensitizer
  Oral bioavailability            Low
  Therapeutic index               Low
  Polarity                        Less
  Molecular size                  Small
